Total Payments
$25,363
2024 Payments
$497.83
Companies
14
Transactions
43
Medicare Patients
1,065
Medicare Billing
$290,104
Payment Breakdown by Category
Consulting$19,810 (78.1%)
Food & Beverage$2,403 (9.5%)
Other$2,325 (9.2%)
Travel$725.47 (2.9%)
Education$99.95 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $19,810 | 8 | 78.1% |
| Food and Beverage | $2,403 | 30 | 9.5% |
| Honoraria | $2,325 | 1 | 9.2% |
| Travel and Lodging | $725.47 | 3 | 2.9% |
| Education | $99.95 | 1 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| CSL Behring | $6,760 | 3 | $0 (2022) |
| Janssen Biotech, Inc. | $4,727 | 7 | $0 (2018) |
| GENZYME CORPORATION | $4,290 | 9 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $2,886 | 6 | $0 (2019) |
| Karyopharm Therapeutics Inc. | $2,698 | 4 | $0 (2024) |
| BeiGene USA, Inc. | $1,710 | 2 | $0 (2022) |
| Adaptive Biotechnologies Corporation | $1,368 | 2 | $0 (2021) |
| Teleflex LLC | $266.95 | 3 | $0 (2024) |
| Celgene Corporation | $214.74 | 2 | $0 (2021) |
| Janssen Scientific Affairs, LLC | $152.79 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $497.83 | 8 | Teleflex LLC ($266.95) |
| 2023 | $582.90 | 5 | GENZYME CORPORATION ($239.75) |
| 2022 | $2,690 | 6 | CSL Behring ($2,080) |
| 2021 | $6,337 | 7 | CSL Behring ($4,680) |
| 2020 | $7,545 | 3 | GENZYME CORPORATION ($3,595) |
| 2019 | $2,983 | 7 | Pharmacyclics LLC, An AbbVie Company ($2,886) |
| 2018 | $4,727 | 7 | Janssen Biotech, Inc. ($4,727) |
All Payment Transactions
43 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/08/2024 | The Binding Site Inc. | EXENT (Device) | Food and Beverage | Cash or cash equivalent | $30.67 | General |
| Category: Immunology | ||||||
| 12/07/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $36.77 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Teleflex LLC | ARROW (Device) | Food and Beverage | In-kind items and services | $34.07 | General |
| Category: INTERVENTIONAL ACCESS | ||||||
| 06/02/2024 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $34.17 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $62.74 | General |
| Category: Oncology | ||||||
| 02/28/2024 | Teleflex LLC | ARROW (Device) | Food and Beverage | In-kind items and services | $108.93 | General |
| Category: INTERVENTIONAL ACCESS | ||||||
| 02/14/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $66.53 | General |
| Category: Oncology | ||||||
| 01/24/2024 | Teleflex LLC | ARROW (Device) | Food and Beverage | In-kind items and services | $123.95 | General |
| Category: INTERVENTIONAL ACCESS | ||||||
| 12/09/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $99.20 | General |
| Category: Oncology | ||||||
| 12/09/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $66.67 | General |
| Category: Oncology | ||||||
| 12/07/2023 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $190.36 | General |
| Category: Oncology | ||||||
| 06/01/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $73.88 | General |
| Category: Oncology | ||||||
| 05/17/2023 | Janssen Scientific Affairs, LLC | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $152.79 | General |
| Category: Oncology | ||||||
| 12/10/2022 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $140.75 | General |
| Category: Oncology | ||||||
| 12/09/2022 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $124.98 | General |
| 12/09/2022 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $84.79 | General |
| Category: Oncology | ||||||
| 08/25/2022 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $143.70 | General |
| Category: Oncology | ||||||
| 06/29/2022 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $115.76 | General |
| Category: Oncology | ||||||
| 01/20/2022 | CSL Behring | — | Consulting Fee | Cash or cash equivalent | $2,080.00 | General |
| 12/11/2021 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $117.81 | General |
| 12/10/2021 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $71.22 | General |
| Category: Oncology | ||||||
| 12/09/2021 | Amgen Inc. | — | Education | In-kind items and services | $99.95 | General |
| 09/07/2021 | CSL Behring | — | Consulting Fee | Cash or cash equivalent | $2,080.00 | General |
| 09/01/2021 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | In-kind items and services | $168.13 | General |
| Category: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | ||||||
| 07/12/2021 | CSL Behring | — | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 276 | 702 | $383,806 | $75,142 |
| 2022 | 8 | 284 | 727 | $381,777 | $76,978 |
| 2021 | 6 | 265 | 718 | $347,127 | $80,781 |
| 2020 | 6 | 240 | 610 | $270,257 | $57,202 |
Total Patients
1,065
Total Services
2,757
Medicare Billing
$290,104
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 167 | 419 | $259,351 | $47,360 | 18.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 46 | 211 | $90,530 | $21,258 | 23.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 21 | $16,905 | $3,084 | 18.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 15 | 16 | $7,062 | $1,564 | 22.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 16 | 20 | $8,068 | $1,480 | 18.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 12 | 15 | $1,890 | $397.05 | 21.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 146 | 456 | $275,627 | $54,990 | 20.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 33 | 157 | $63,908 | $13,738 | 21.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 14 | $11,046 | $2,389 | 21.6% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 22 | 24 | $9,546 | $1,902 | 19.9% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2022 | 19 | 21 | $7,413 | $1,394 | 18.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 13 | 15 | $6,345 | $1,373 | 21.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 19 | 22 | $2,808 | $605.86 | 21.6% |
| 38221 | Biopsy of bone marrow | Facility | 2022 | 18 | 18 | $5,084 | $588.43 | 11.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 116 | 411 | $210,080 | $51,595 | 24.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 57 | 198 | $83,898 | $17,699 | 21.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 26 | 27 | $22,131 | $4,680 | 21.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 29 | 36 | $15,806 | $3,253 | 20.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 19 | 25 | $8,275 | $2,127 | 25.7% |
| 38222 | Diagnostic aspirations and biopsies of bone marrow | Facility | 2021 | 18 | 21 | $6,937 | $1,426 | 20.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 89 | 266 | $127,002 | $25,036 | 19.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 49 | 222 | $92,490 | $20,084 | 21.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 27 | 27 | $21,969 | $4,742 | 21.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 32 | 45 | $9,251 | $3,109 | 33.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 27 | 31 | $13,448 | $2,914 | 21.7% |
About Dr. Andrew Branagan, M.D
Dr. Andrew Branagan, M.D is a Hematology & Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/13/2009. The National Provider Identifier (NPI) number assigned to this provider is 1679707053.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Branagan, M.D has received a total of $25,363 in payments from pharmaceutical and medical device companies, with $497.83 received in 2024. These payments were reported across 43 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($19,810).
As a Medicare-enrolled provider, Branagan has provided services to 1,065 Medicare beneficiaries, totaling 2,757 services with total Medicare billing of $290,104. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Boston, MA
- Active Since 05/13/2009
- Last Updated 03/17/2018
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1679707053
Products in Payments
- IMBRUVICA (Drug) $4,727
- SARCLISA (Biological) $4,290
- Imbruvica (Drug) $2,886
- XPOVIO (Drug) $2,698
- BRUKINSA (Drug) $1,710
- clonoSEQ (Device) $1,368
- ARROW (Device) $266.95
- DARZALEX (Biological) $152.79
- Pomalyst (Drug) $96.93
- ELREXFIO (Drug) $34.17
- EXENT (Device) $30.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Boston
Dr. Julio Hajdenberg, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Eric Jacobsen, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Paul Richardson, Md, MD
Hematology & Oncology — Payments: $920,265
Hematology & Oncology $920,265
Matthew Davids, M.d, M.D
Hematology & Oncology — Payments: $808,362
Hematology & Oncology $808,362
David Avigan, M.d, M.D
Hematology & Oncology — Payments: $679,225
Hematology & Oncology $679,225
Anthony Letai, Md, MD
Hematology & Oncology — Payments: $569,795
Hematology & Oncology $569,795